A new study published in the Journal of Nutrition and Dietary Supplements has found that the natural dietary supplements, Sugar Crush and Sugar Crush Daily, were effective in reducing blood glucose levels in patients with type 2 diabetes...
A new study out of Be'er Sheva University, Israel, has found that adolescent's body mass index (BMI) can predict early occurrences of diabetes and heart disease in adulthood. The large cohort study which followed 37,000 teenagers for 17 years found...
The results of three large randomized clinical trials examining the predictors of new-onset type 2 diabetes in patients treated with Lipitor (Atorvastatin) were published in the Journal of the American College of Cardiology.
The researchers found that patients treated with high-doses of atorvastatin...
A new study designed to evaluate the effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes has found that continuous glucose monitoring both reduces the amount of time spent by type 1 diabetes patients in hypoglycemia and improves HbA1c levels. The results appear in the April addition of Diabetes Care....
An International Diabetes Federation (IDF) paper calls for bariatric surgery to be considered earlier in the treatment of eligible type 2 diabetes patients, to help stem the serious complications that can result from diabetes. The position paper was presented to leading experts at the 2nd World Congress on Interventional Therapies for Type 2 Diabetes ...
Sanofi-aventis and Columbia University Medical Center announced a three-year research collaboration for the development of innovative diabetes medicines. This research collaboration, with the laboratory of Dr. Gerard Karsenty, will investigate the role of the osteoblast-secreted peptide, osteocalcin, in diabetes management...
Novo Nordisk is partnering with 2011 IZOD IndyCar Series driver Charlie Kimball to launch the educational program, Drive the Switch, encouraging diabetes patients who use insulin and caregivers to pledge to talk to their healthcare professional about options for insulin delivery, like the prefilled insulin pen device...
New clinical trial data just published in Pediatric Diabetes shows that Levemir (insulin detemir), Novo Nordisk’s basal insulin analogue, is an equally efficacious treatment option for two to five year-old children with type 1 diabetes, compared with human basal insulin, but is associated with lower hypoglycemic risk. Children with type 1 diabetes who are aged under six years...
XOMA Ltd. announced that its phase 2b trial of XOMA 052 in type 2 diabetes patients did not achieve the primary endpoint of reduction of HbA1c after six monthly treatments with XOMA 052 compared to placebo.
Biological activity of XOMA 052 supporting its potential...
A new study conducted by the Institute for Alternative Futures (IAF) identified California, Texas, Florida, New York, Ohio, Illinois, Georgia, Pennsylvania, North Carolina and Michigan as “diabetes hot spots,” where the burden of diabetes will be greatest in the next 15 years...